These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 29628274)
21. Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice. Komori T; Tanaka M; Furuta H; Akamizu T; Miyajima A; Morikawa Y Diabetologia; 2015 Aug; 58(8):1868-76. PubMed ID: 25972231 [TBL] [Abstract][Full Text] [Related]
23. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Lee WH; Loo CY; Traini D; Young PM Expert Opin Drug Deliv; 2015 Jun; 12(6):1009-26. PubMed ID: 25912721 [TBL] [Abstract][Full Text] [Related]
24. Macrophage MicroRNAs as Therapeutic Targets for Atherosclerosis, Metabolic Syndrome, and Cancer. Wei Y; Zhu M; Schober A Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899293 [TBL] [Abstract][Full Text] [Related]
25. Interactions with the macrophages: An emerging targeted approach using novel drug delivery systems in respiratory diseases. Mehta M; Deeksha ; Sharma N; Vyas M; Khurana N; Maurya PK; Singh H; Andreoli de Jesus TP; Dureja H; Chellappan DK; Gupta G; Wadhwa R; Collet T; Hansbro PM; Dua K; Satija S Chem Biol Interact; 2019 May; 304():10-19. PubMed ID: 30849336 [TBL] [Abstract][Full Text] [Related]
26. Recent advances in endocrine metabolic immune disorders drug targeting: an editorial overview. Magrone T; Jirillo E Endocr Metab Immune Disord Drug Targets; 2015; 15(1):1-8. PubMed ID: 25800124 [TBL] [Abstract][Full Text] [Related]
27. Passive lung-targeted drug delivery systems via intravenous administration. Wei Y; Zhao L Pharm Dev Technol; 2014 Mar; 19(2):129-36. PubMed ID: 23336716 [TBL] [Abstract][Full Text] [Related]
28. Liposomal drug delivery systems: from concept to clinical applications. Allen TM; Cullis PR Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225 [TBL] [Abstract][Full Text] [Related]
29. Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases. Singh A; Talekar M; Raikar A; Amiji M J Control Release; 2014 Sep; 190():515-30. PubMed ID: 24747762 [TBL] [Abstract][Full Text] [Related]
36. Targeting bile-acid signalling for metabolic diseases. Thomas C; Pellicciari R; Pruzanski M; Auwerx J; Schoonjans K Nat Rev Drug Discov; 2008 Aug; 7(8):678-93. PubMed ID: 18670431 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic targeting strategies using endogenous cells and proteins. Parayath NN; Amiji MM J Control Release; 2017 Jul; 258():81-94. PubMed ID: 28483514 [TBL] [Abstract][Full Text] [Related]
38. Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review. Cheraghi M; Negahdari B; Daraee H; Eatemadi A Biomed Pharmacother; 2017 Feb; 86():316-323. PubMed ID: 28011379 [TBL] [Abstract][Full Text] [Related]
39. Immune regulation of metabolic homeostasis in health and disease. Brestoff JR; Artis D Cell; 2015 Mar; 161(1):146-160. PubMed ID: 25815992 [TBL] [Abstract][Full Text] [Related]
40. Selective delivery of drugs encapsulated in liposomes: natural targeting to macrophages involved in various disease states. Schroit AJ; Hart IR; Madsen J; Fidler IJ J Biol Response Mod; 1983; 2(2):97-100. PubMed ID: 6644336 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]